Lambda Biologics provides state-of-the-art organoid-based disease modeling and drug evaluation services. Utilizing human induced pluripotent stem cells (iPSCs), our platform generates three-dimensional organoids that accurately recapitulate organ structure and function. This enables precise modeling of disease mechanisms and predictive assessment of therapeutic compounds.
Physiological Relevance
Organoids mimic human tissue architecture and cellular heterogeneity, providing more translationally relevant data than traditional 2D cultures or animal models.
Broad Disease Coverage
Applicable to oncology and disorders of the skin, intestines, liver, lungs, and other key organ systems.
Ethically Aligned Research
Built on FDA-aligned New Approach Methodologies (NAMs) to replace or reduce animal testing and support modern regulatory pathways.
Predictive Drug Assessment
Evaluate compound efficacy and toxicity in a controlled, human-like environment.
Lambda Biologics Organoid Based Disease Model
Human-relevant organoid models for studying disease mechanisms, evaluating therapeutic responses, and supporting predictive preclinical research.
